Abciximab Biosimilar - Research Grade

Human

GPIIb/IIIa

>1mg/ml

Human IgG1 Fab-Kappa

https://www.imgt.org/mAb-DB/

ICH3002

P08514

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of abciximab, supplied strictly for research use only. It is built around the platelet integrin GPIIb/IIIa (integrin alphaIIb-beta3) target and reproduces the antigen-binding activity of the originator, which is itself a Fab fragment directed against this receptor. It is provided as a research-grade reagent, not the clinical drug, and is not intended for human or veterinary use. Because it is furnished unconjugated, it is well suited to in-vitro binding studies, receptor-occupancy and neutralization assays, competition and blocking experiments, and as a defined reference or control antibody when characterizing anti-GPIIb/IIIa reagents or biosimilar candidates. Researchers developing conjugates, fusion formats, or ADC-style constructs can use it as a starting binder. The material is offered at low endotoxin levels (research grade typically <1 EU/mg, ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay scale-up, in-vitro standardization, and preclinical workflows. Lot-to-lot consistency and defined specificity make it a practical building block for platelet-biology and antithrombotic mechanism research. GPIIb/IIIa is the platelet integrin alphaIIb-beta3, encoded by ITGA2B (alphaIIb; UniProt P08514) and ITGB3 (beta3). It is the most abundant receptor on the platelet surface and is largely restricted to platelets and their megakaryocyte precursors. In resting platelets the receptor sits in a low-affinity, bent conformation. Platelet activation by agonists such as thrombin, ADP, or collagen drives inside-out signaling that switches the integrin to a high-affinity, extended state capable of binding fibrinogen and von Willebrand factor via RGD and related recognition motifs. Fibrinogen cross-bridging between adjacent platelets mediates aggregation and thrombus growth, while ligand engagement also initiates outside-in signaling that supports spreading, granule secretion, and clot retraction. As the final common pathway of platelet aggregation, GPIIb/IIIa is a key antithrombotic drug target and is defective in Glanzmann thrombasthenia.

GPalpha IIb, GPIIb, Platelet membrane glycoprotein IIb, Integrin alpha-IIb, ITGA2B, GP2B, ITGAB

Detects human GPIIb/IIIa. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Abciximab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Abciximab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Abciximab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Abciximab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Abciximab that binds human GPIIb/IIIa.